Actelion
Up to 135 Will cut about 5% of its approximately 2,500 employees as part of a plan to reduce spending by refocusing R&D activities on specialty areas. The cuts will affect R&D and administration.
AMAG Pharmaceuticals 45
Will restructure and reduce headcount by 26% to about 130 by year end to focus on advancing anemia drug Feraheme (ferumoxytol) and expanding its portfolio with commercial-stage products.
BioInvent International 21
Will restructure and reduce headcount by 24% to 68 following its June decision to discontinue development of TB-402, which is expected to save $2.1 million annually.
Infinity Pharmaceuticals 30
Reduced headcount by about 20% to 160 after it discontinued development of cancer compound saridegib and terminated a deal with Purdue Pharma and Mundipharma.
Dendreon 600
Will restructure and reduce headcount by 40%. It will close its Morris Plains, NJ, manufacturing facility, which is one of three facilities producing prostate cancer drug Provenge (sipuleucel-T), the company's only drug on the market.
Pharming Group
At least 20 Will restructure its Dutch operations and reduce headcount to align resources to transition from a mainly internal researchdriven model to a market-driven, external R&D model.
QLT 146
Will restructure and reduce headcount by 68% to 68 to focus on ophthalmic candidate QLT091001.
Savient Pharmaceuticals 60
Will restructure and reduce headcount by about 35% to improve operational efficiencies while focusing on the commercialization of Krystexxa (pegloticase).
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